Welcome to our dedicated page for Biora Therapeutics news (Ticker: $BIOR), a resource for investors and traders seeking the latest updates and insights on Biora Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biora Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biora Therapeutics's position in the market.
Biora Therapeutics, Inc. (Nasdaq: BIOR) will report financial results and provide a corporate update for Q1 2024 on May 15, 2024. The company focuses on therapeutic delivery and will host a webcast and conference call after the market close. Investors can access the call online for 60 days.
Biora Therapeutics, Inc. (Nasdaq: BIOR) will present clinical data on the device function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024. The presentation will include results of human device function studies in healthy volunteers and patients with UC. The abstract will be presented by Shaoying Nikki Lee, PhD, Director of Clinical and Translational Science at Biora Therapeutics, Inc.
Biora Therapeutics, Inc. (Nasdaq: BIOR) announces the completion of dosing for multiple-ascending dose cohorts in the clinical trial of BT-600 for potential treatment of ulcerative colitis. Final results expected in late Q2 2024. The trial evaluated daily doses of BT-600 for seven days at 5 mg and 10 mg tofacitinib or placebo in healthy adult participants. Positive interim results from the single-ascending dose portion have been previously shared.
